{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:50:15Z","timestamp":1775746215452,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejso.2018.07.057","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T21:54:10Z","timestamp":1533160450000},"page":"1619-1623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Alex","family":"Barenboim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Lahat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravit","family":"Geva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Nachmany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Nakache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaacov","family":"Goykhman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Brazowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galia","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Isakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Klausner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Lubezky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2018.07.057_bib1","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/cncr.27514","article-title":"Annual report to the nation on the status of cancer, 1975\u20132008, featuring cancers associated with excess weight and lack of sufficient physical activity","volume":"118","author":"Eheman","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2018.07.057_bib2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9610(05)80406-4","article-title":"Prognostic indicators for survival after resection of pancreatic adenocarcinoma","volume":"165","author":"Geer","year":"1993","journal-title":"Am J Surg"},{"issue":"8","key":"10.1016\/j.ejso.2018.07.057_bib3","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.6004\/jnccn.2014.0106","article-title":"Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines","volume":"12","author":"Tempero","year":"2014","journal-title":"J\u00a0Natl Compr Cancer Netw JNCCN"},{"issue":"8","key":"10.1016\/j.ejso.2018.07.057_bib4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1056\/NEJMc1107627","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"365","author":"Vaccaro","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2018.07.057_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11605-017-3556-1","article-title":"Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy","volume":"22","author":"Kluger","year":"2018","journal-title":"J Gastrointest Surg"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.ejso.2018.07.057_bib6","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1245\/s10434-015-4851-2","article-title":"Resectability after first-line FOLFIRINOX in initially unresectable locally advanced pancreatic cancer: a single-center experience","volume":"22","author":"Nitsche","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2018.07.057_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4174\/astr.2017.93.4.186","article-title":"Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer","volume":"93","author":"Kim","year":"2017","journal-title":"Ann Surg Treat Res"},{"issue":"3","key":"10.1016\/j.ejso.2018.07.057_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","article-title":"Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients","volume":"264","author":"Hackert","year":"2016","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2018.07.057_bib9","doi-asserted-by":"crossref","first-page":"e161137","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.ejso.2018.07.057_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00280-016-3121-8","article-title":"Impact of treatment duration of neoadjuvant FIRINOX in patients with borderline resectable pancreatic cancer: a pilot trial","volume":"78","author":"Okada","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"issue":"28","key":"10.1016\/j.ejso.2018.07.057_bib11","doi-asserted-by":"crossref","first-page":"46337","DOI":"10.18632\/oncotarget.17940","article-title":"Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen","volume":"8","author":"Yoo","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.ejso.2018.07.057_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/bjc.2016.45","article-title":"Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer","volume":"114","author":"Stein","year":"2016","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2018.07.057_bib13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jso.23921","article-title":"Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability","volume":"111","author":"Nanda","year":"2015","journal-title":"J\u00a0Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2018.07.057_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1245\/s10434-014-3898-9","article-title":"FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort","volume":"22","author":"Marthey","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2018.07.057_bib15","first-page":"232","article-title":"FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience","volume":"13","author":"Moorcraft","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.ejso.2018.07.057_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Ferrone","year":"2015","journal-title":"Ann Surg"},{"issue":"Suppl.\u00a03","key":"10.1016\/j.ejso.2018.07.057_bib17","doi-asserted-by":"crossref","first-page":"S1196","DOI":"10.1245\/s10434-015-4783-x","article-title":"Pathologic major response after FOLFIRINOX is prognostic for patients secondary resected for borderline or locally advanced pancreatic adenocarcinoma: an AGEO-French, prospective, multicentric cohort","volume":"22","author":"Pietrasz","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2018.07.057_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1634\/theoncologist.2013-0273","article-title":"Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?","volume":"19","author":"Christians","year":"2014","journal-title":"The Oncologist"},{"issue":"4","key":"10.1016\/j.ejso.2018.07.057_bib19","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1245\/s10434-014-4225-1","article-title":"Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas","volume":"22","author":"Blazer","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2018.07.057_bib20","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1097\/PAS.0000000000000738","article-title":"Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival","volume":"40","author":"Lee","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"14","key":"10.1016\/j.ejso.2018.07.057_bib21","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318312605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798318312605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:28:29Z","timestamp":1760059709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798318312605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0748798318312605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2018.07.057","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2018.07.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}